

**duloxetine (Yentreve<sup>®</sup>)**

**No. 119/04**

**Eli Lilly and Company**

## Summary of Recommendation

11 October 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**Advice:** following a full submission.

Duloxetine is accepted for restricted use within NHS Scotland for the treatment of moderate to severe stress urinary incontinence (SUI). It should be used only as part of an overall management strategy for SUI in addition to pelvic floor muscle training. Patients should be reviewed after 12 weeks of therapy to assess progress and determine whether it is appropriate to continue treatment.

Because of the short duration of treatment in the studies supplied, it is recommended that the manufacturers collect further data on the long-term effects of this pharmacological approach to the management of SUI.

Professor David H Lawson  
Chairman